FY2027 EPS Forecast for TG Therapeutics Decreased by Analyst

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities researchers at B. Riley reduced their FY2027 EPS estimates for TG Therapeutics in a research report issued on Monday, November 4th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will post earnings of $2.46 per share for the year, down from their prior forecast of $2.48. B. Riley currently has a "Buy" rating and a $34.00 price target on the stock. The consensus estimate for TG Therapeutics' current full-year earnings is $0.13 per share. B. Riley also issued estimates for TG Therapeutics' FY2028 earnings at $3.41 EPS.

A number of other brokerages have also recently commented on TGTX. The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Tuesday. TD Cowen initiated coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 price objective on the stock. Finally, HC Wainwright increased their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a "buy" rating in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, TG Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $37.67.

TG Therapeutics Stock Up 4.3 %

TGTX traded up $1.16 during trading hours on Thursday, hitting $28.33. 2,032,684 shares of the company's stock were exchanged, compared to its average volume of 3,643,486. The stock has a market cap of $4.39 billion, a price-to-earnings ratio of -271.70 and a beta of 2.19. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58. The stock's 50-day moving average is $23.65 and its two-hundred day moving average is $20.30. TG Therapeutics has a 1-year low of $9.81 and a 1-year high of $28.41.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. During the same period in the previous year, the company posted $0.73 EPS. The firm's revenue for the quarter was down 49.4% on a year-over-year basis.

Institutional Investors Weigh In On TG Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Quest Partners LLC acquired a new stake in TG Therapeutics during the 3rd quarter worth approximately $246,000. Thrivent Financial for Lutherans bought a new stake in shares of TG Therapeutics in the 3rd quarter valued at $2,450,000. Mutual of America Capital Management LLC acquired a new stake in shares of TG Therapeutics during the third quarter worth $469,000. Empowered Funds LLC raised its stake in TG Therapeutics by 3.1% during the third quarter. Empowered Funds LLC now owns 46,431 shares of the biopharmaceutical company's stock worth $1,086,000 after buying an additional 1,386 shares during the last quarter. Finally, KBC Group NV lifted its holdings in TG Therapeutics by 30.5% in the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company's stock valued at $109,000 after buying an additional 1,092 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.